Treatment of diastolic dysfunction in hypertension

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 8, 2012, Pages 613-618

  Ginelli, P ^a   Bella, J N ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Diastolic function; Heart failure; Hypertension; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DIASTOLE; DIASTOLIC HEART FAILURE; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; MORTALITY; PATHOPHYSIOLOGY; SHORT SURVEY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84864068784     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.04.016     Document Type: Short Survey

References (39)

1. Bella J.N., Palmieri V., Roman M.J., Liu J.E., Welty T.K., Lee E.T., et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the strong heart study. Circulation 2002 Apr 23, 105(16):1928-1933.
2. Aurigemma G.P., Gottdiener J.S., Shemanski L., Gardin J., Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001 Mar 15, 37(4):1042-1048.
3. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. J Am Med Assoc 2003 Jan 8, 289(2):194-202.
4. Kane G.C., Karon B.L., Mahoney D.W., Redfield M.M., Roger V.L., Burnett J.C., et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. J Am Med Assoc 2011 Aug 24, 306(8):856-863.
5. Schillaci G., Pasqualini L., Verdecchia P., Vaudo G., Marchesi S., Porcellati C., et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002 Jun 19, 39(12):2005-2011.
6. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 Jul 20, 355(3):251-259.
7. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002 Mar 19, 105(11):1387-1393.
8. Solomon S.D., Verma A., Desai A., Hassanein A., Izzo J., Oparil S., et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 2010 Feb, 55(2):241-248.
9. Vasan R.S., Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996 Sep 9, 156(16):1789-1796.
10. Bella J.N. Epidemiology of left ventricular hypertrophy and dilated cardiomyopathy. Molecular mechanisms of cardiac hypertrophy and failure 2005, 477-500. CRC Press. 1st ed. R.A. Walsh (Ed.).
11. Cutler J.A., Sorlie P.D., Wolz M., Thom T., Fields L.E., Roccella E.J. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008 Nov, 52(5):818-827.
12. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (esh) and of the European society of cardiology (ESC). Eur Heart J 2007 Jun 2007, 28(12):1462-1536.
13. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 2003 May 21, 289(19):2560-2572.
14. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur J Heart Fail 2008 Oct, 10(10):933-989.
15. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2005 Sep 20, 46(6):e1-82.
16. Wachtell K., Bella J.N., Rokkedal J., Palmieri V., Papademetriou V., Dahlof B., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (life) study. Circulation 2002 Mar 5, 105(9):1071-1076.
17. Ma T.K., Kam K.K., Yan B.P., Lam Y.Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010 Jul, 160(6):1273-1292.
18. Terpstra W.F., May J.F., Smit A.J., de Graeff P.A., Havinga T.K., van den Veur E., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001 Feb, 19(2):303-309.
19. Yip G.W., Wang M., Wang T., Chan S., Fung J.W., Yeung L., et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008 May, 94(5):573-580.
20. Muller-Brunotte R., Kahan T., Malmqvist K., Ring M., Edner M. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish irbesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA). Am J Hypertens 2006 Sep, 19(9):927-936.
21. Solomon S.D., Janardhanan R., Verma A., Bourgoun M., Daley W.L., Purkayastha D., et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007 Jun 23, 369(9579):2079-2087.
22. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 Dec 4, 359(23):2456-2467.
23. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003 Sep 6, 362(9386):777-781.
24. Wachtell K., Palmieri V., Gerdts E., Bella J.N., Aurigemma G.P., Papademetriou V., et al. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE study). Am J Cardiol 2010 Oct 1, 106(7):999-1005.
25. Bonow R.O., Udelson J.E. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992 Sep 15, 117(6):502-510.
26. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 2002 Mar 26, 105(12):1503-1508.
27. Nodari S., Metra M., Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003 Oct, 5(5):621-627.
28. Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005 Feb, 26(3):215-225.
29. Aronow W.S., Ahn C., Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or =40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997 Jul 15, 80(2):207-209.
30. Takeda Y., Fukutomi T., Suzuki S., Yamamoto K., Ogata M., Kondo H., et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004 Aug 15, 94(4):448-453.
31. Ventura H., Loyalka P., Smart F.W. Treatment of the hypertensive patient with microvascular angina. Curr Opin Cardiol 1999 Sep, 14(5):370-374.
32. Tapp R.J., Sharp A., Stanton A.V., O'Brien E., Chaturvedi N., Poulter N.R., et al. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (anglo-scandinavian cardiac outcomes trial) substudy. J Am Coll Cardiol 2010 Apr 27, 55(17):1875-1881.
33. Setaro J.F., Zaret B.L., Schulman D.S., Black H.R., Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990 Oct 15, 66(12):981-986.
34. Ohtani T., Ohta M., Yamamoto K., Mano T., Sakata Y., Nishio M., et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007 Feb, 292(2):R946-R954.
35. Izawa H., Murohara T., Nagata K., Isobe S., Asano H., Amano T., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005 Nov 8, 112(19):2940-2945.
36. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004 Aug 3, 110(5):558-565.
37. [accessed 29.09.11]. http://www.topcatstudy.com.
38. Galderisi M. Diagnosis and management of left ventricular diastolic dysfunction in the hypertensive patient. Am J Hypertens 2011 May, 24(5):507-517.
39. Wang W., Bodiga S., Das S.K., Lo J., Patel V., Oudit G.Y. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 2011 Jun 3.